Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286005 | 1.00 | MEN1 (0.65) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL29881755 | 1.00 | MEN1 (0.65) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL1286007 | 1.00 | MEN1 (0.65) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL31011372 | 1.00 | MEN1 (0.65) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL6464270 | 0.87 | MEN1 (0.64) | MEN1KMT2ALMNAGAAHDAC3 | |
| Undecanoate SCHEMBL27542118 | 0.86 | CNR2 (0.56) | MEN1KMT2A | |
| SCHEMBL1318685 | 0.86 | MEN1 (0.65) | MEN1KMT2ALMNAGAA | |
| SCHEMBL29495794 | 0.86 | MEN1 (0.65) | MEN1KMT2ALMNAGAA | |
| SCHEMBL10793648 | 0.85 | MEN1 (0.61) | MEN1KMT2ALMNAGAASSTR4 | |
| SCHEMBL14484271 | 0.84 | LMNA (0.64) | MEN1KMT2ALMNAGAAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3807243-B1 | A NOVEL PROCESS FOR THE PREPARATION OF TAPENTADOL | PHARMATHEN SA (GR) | 2024-05-22 | — | — | EP | disclosed |
| EP-3810582-B1 | A ONE-POT ORGANO-PSEUDOCATALYTIC C-H ACTIVATION APPROACH FOR THE PREPARATION OF VORTIOXETINE AND VORTIOXETINE INTERMEDIATE | VIO AG PHARMACEUTICALS S A (GR) | 2024-01-03 | — | — | EP | disclosed |
| US-11851503-B2 | Antiplasmodial compounds | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. | 2023-02-09 | — | — | US | disclosed |
| EP-4073242-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | Kumquat Biosciences Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | CHAN YEUNG Y | 2006-05-18 | — | — | US | disclosed |
| US-7034152-B2 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1644384-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1747959-A | Process for the preparation of the antiviral agent [ 1S- (1 α, 3 α, 4 β) ] -2-amino-1, 9-dihydro-9- [ 4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl ] -6H-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2006-03-15 | — | — | CN | disclosed |
| US-20050272932-A1 | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-08 | — | — | US | disclosed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | disclosed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | MEN1 4428/4885KMT2A 2681/4885LMNA 4734/4885 |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | MEN1 3108/4885KMT2A 2959/4885LMNA 2046/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | MEN1 4405/4885KMT2A 2377/4885LMNA 4799/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | MEN1 4428/4885KMT2A 2681/4885LMNA 4734/4885 |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | NFATC1, MYD88, ICOS | MEN1 2651/4885KMT2A 3546/4885LMNA 3242/4885 |
| US-11851503-B2 | Antiplasmodial compounds | MGST3, G6PD, GPX4 | MEN1 4531/4885KMT2A 3968/4885LMNA 1059/4885 |
| US-20050272932-A1 | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation | SAMHD1, TYMP, SEPTIN9 | MEN1 2149/4885KMT2A 2347/4885LMNA 2924/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | MEN1 4428/4885KMT2A 2681/4885LMNA 4734/4885 |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | MEN1 3287/4885KMT2A 2653/4885LMNA 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.